Cargando…
Precision Vaccinology Approaches for the Development of Adjuvanted Vaccines Targeted to Distinct Vulnerable Populations
Infection persists as one of the leading global causes of morbidity and mortality, with particular burden at the extremes of age and in populations who are immunocompromised or suffer chronic co-morbid diseases. By focusing discovery and innovation efforts to better understand the phenotypic and mec...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305121/ https://www.ncbi.nlm.nih.gov/pubmed/37376214 http://dx.doi.org/10.3390/pharmaceutics15061766 |
_version_ | 1785065658576273408 |
---|---|
author | Lee, Branden Nanishi, Etsuro Levy, Ofer Dowling, David J. |
author_facet | Lee, Branden Nanishi, Etsuro Levy, Ofer Dowling, David J. |
author_sort | Lee, Branden |
collection | PubMed |
description | Infection persists as one of the leading global causes of morbidity and mortality, with particular burden at the extremes of age and in populations who are immunocompromised or suffer chronic co-morbid diseases. By focusing discovery and innovation efforts to better understand the phenotypic and mechanistic differences in the immune systems of diverse vulnerable populations, emerging research in precision vaccine discovery and development has explored how to optimize immunizations across the lifespan. Here, we focus on two key elements of precision vaccinology, as applied to epidemic/pandemic response and preparedness, including (a) selecting robust combinations of adjuvants and antigens, and (b) coupling these platforms with appropriate formulation systems. In this context, several considerations exist, including the intended goals of immunization (e.g., achieving immunogenicity versus lessening transmission), reducing the likelihood of adverse reactogenicity, and optimizing the route of administration. Each of these considerations is accompanied by several key challenges. On-going innovation in precision vaccinology will expand and target the arsenal of vaccine components for protection of vulnerable populations. |
format | Online Article Text |
id | pubmed-10305121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103051212023-06-29 Precision Vaccinology Approaches for the Development of Adjuvanted Vaccines Targeted to Distinct Vulnerable Populations Lee, Branden Nanishi, Etsuro Levy, Ofer Dowling, David J. Pharmaceutics Review Infection persists as one of the leading global causes of morbidity and mortality, with particular burden at the extremes of age and in populations who are immunocompromised or suffer chronic co-morbid diseases. By focusing discovery and innovation efforts to better understand the phenotypic and mechanistic differences in the immune systems of diverse vulnerable populations, emerging research in precision vaccine discovery and development has explored how to optimize immunizations across the lifespan. Here, we focus on two key elements of precision vaccinology, as applied to epidemic/pandemic response and preparedness, including (a) selecting robust combinations of adjuvants and antigens, and (b) coupling these platforms with appropriate formulation systems. In this context, several considerations exist, including the intended goals of immunization (e.g., achieving immunogenicity versus lessening transmission), reducing the likelihood of adverse reactogenicity, and optimizing the route of administration. Each of these considerations is accompanied by several key challenges. On-going innovation in precision vaccinology will expand and target the arsenal of vaccine components for protection of vulnerable populations. MDPI 2023-06-19 /pmc/articles/PMC10305121/ /pubmed/37376214 http://dx.doi.org/10.3390/pharmaceutics15061766 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lee, Branden Nanishi, Etsuro Levy, Ofer Dowling, David J. Precision Vaccinology Approaches for the Development of Adjuvanted Vaccines Targeted to Distinct Vulnerable Populations |
title | Precision Vaccinology Approaches for the Development of Adjuvanted Vaccines Targeted to Distinct Vulnerable Populations |
title_full | Precision Vaccinology Approaches for the Development of Adjuvanted Vaccines Targeted to Distinct Vulnerable Populations |
title_fullStr | Precision Vaccinology Approaches for the Development of Adjuvanted Vaccines Targeted to Distinct Vulnerable Populations |
title_full_unstemmed | Precision Vaccinology Approaches for the Development of Adjuvanted Vaccines Targeted to Distinct Vulnerable Populations |
title_short | Precision Vaccinology Approaches for the Development of Adjuvanted Vaccines Targeted to Distinct Vulnerable Populations |
title_sort | precision vaccinology approaches for the development of adjuvanted vaccines targeted to distinct vulnerable populations |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305121/ https://www.ncbi.nlm.nih.gov/pubmed/37376214 http://dx.doi.org/10.3390/pharmaceutics15061766 |
work_keys_str_mv | AT leebranden precisionvaccinologyapproachesforthedevelopmentofadjuvantedvaccinestargetedtodistinctvulnerablepopulations AT nanishietsuro precisionvaccinologyapproachesforthedevelopmentofadjuvantedvaccinestargetedtodistinctvulnerablepopulations AT levyofer precisionvaccinologyapproachesforthedevelopmentofadjuvantedvaccinestargetedtodistinctvulnerablepopulations AT dowlingdavidj precisionvaccinologyapproachesforthedevelopmentofadjuvantedvaccinestargetedtodistinctvulnerablepopulations |